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used to assess sarcopenia. The prevalence of sarcopenia 
was 18.0%. Insulin treatment was shown to be protective 
against the annual decline of SMI (standardized β 0.195; 
p = 0.025) even after adjusting for covariates, including 
age, gender, duration of diabetes, and body mass index. In a 
cohort matched by propensity scores, insulin treatment sig-
nificantly increased the 1-year change in SMI (mean ± SE) 
compared with non-insulin-treated group (2.40 ± 0.98% vs. 
−0.43 ± 0.98%; p = 0.050). Our data suggest that insulin 
treatment could attenuate the progression of sarcopenia in 
patients with type 2 diabetes.
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Abstract Sarcopenia is defined as an age-related loss of 
skeletal muscle mass and strength, and is a major cause 
of disability and mobility limitations. Recent studies have 
demonstrated that type 2 diabetes and insulin signaling 
deficiencies contribute to the progression of sarcopenia, 
suggesting that a sufficient supply of insulin to the skeletal 
muscles may be important for the maintenance of mus-
cle function; however, little has been reported regarding 
whether insulin treatment can protect against sarcopenia. 
We conducted a retrospective observational study to exam-
ine the impact of insulin treatment on the muscle mass of 
patients with type 2 diabetes. A total of 312 patients (mean 
age: 64 ± 11 years; 40.8% female; 27.6% treated with insu-
lin) were studied in this retrospective observational study. 
Skeletal muscle index (SMI) and grip strength (kg) were 
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Introduction
Sarcopenia is defined as the loss of skeletal muscle mass 
and strength that occurs with aging and is a major cause 
of disability and mobility limitations [1–3]. Although it 
has been clearly shown that sarcopenia has an adverse 
effect on mobility, the quality of life (QOL), and mortal-
ity [2, 4], the diagnostic thresholds of muscle mass and 
strength remain controversial. In 2010, the European 
Working Group on Sarcopenia in Older People was the 
first to achieve a consensus on the definition of sarcope-
nia, including the diagnostic thresholds for muscle mass 
and strength [1]. Subsequently, similar definitions were 
created by the International Working Group on Sarcope-
nia [2] and Asian Working Group for Sarcopenia (the cri-
teria for Asian population) [3]. However, these definitions 
were determined based on the results of various studies 
using individual definitions of sarcopenia and diagnostic 
thresholds in each study. In addition, it remains uncertain 
whether the consensus made much such groups is appli-
cable to patients of any race or those with chronic dis-
eases. Of the chronic diseases, diabetes has been reported 
to be one of the significant contributors to the exacerba-
tion of sarcopenia [5–8]. The Health, Aging, and Body 
Composition Study revealed that elderly patients with 
diabetes have lower muscle strength than non-diabetic 
subjects [6]. Using a longitudinal survey, this research 
group also reported that patients with diabetes have an 
increased risk for the excessive loss of both skeletal mus-
cle mass and strength, particularly in the lower extremi-
ties [7, 8]. Given these findings, patients with diabetes 
are thought to be susceptible to mobility-related disabili-
ties through the loss of muscle mass and strength primar-
ily in the lower extremities.
Resistance training with protein supplementation was 
reported to be the most effective form of treatment for 
sarcopenia, [9, 10]. Pharmaceutical therapies have also 
been studied; however, there is insufficient evidence sup-
porting effective medication for the treatment of sarcope-
nia [11]. In diabetic patients, poor glycemic control and 
insulin resistance are independently associated with the 
decline of skeletal muscle mass among elderly patients 
with diabetes [12, 13]. Consequently, these abnormali-
ties could be considered a therapeutic target for sarcope-
nia. Indeed, it was reported that insulin sensitizers may 
attenuate the decline in muscle mass in patients with dia-
betes [14]. In addition, low endogenous insulin secretion 
was also associated with muscle mass among patients 
with diabetes [15]. Furthermore, supraphysiological 
hyperinsulinemia has been reported to be necessary for 
the stimulation of muscle protein synthesis and anabolic 
signaling in elderly subjects [16], suggesting that suf-
ficient insulin supply could provide protection against 
the progression of sarcopenia in patients with diabetes. 
Therefore, we investigated the impact of insulin treatment 
on sarcopenia in patients with type 2 diabetes.
Methods
Subjects
We screened type 2 diabetic patients aged older than 
20 years who regularly visited the Tokyo Medical and 
Dental University Hospital for at least 1 year and had 
undergone a whole-body dual-energy X-ray absorptiom-
etry (DXA) from July 1, 2012 to December 31, 2015. 
As shown in Figs. 1, 2, 374 patients aged more than 20 
years at our hospital had undergone a whole-body DXA 
during the study period, of whom 1305 patients were 
diagnosed as having type 2 diabetes. We selected 352 
patients with type 2 diabetes who had undergone a sec-
ond DXA measurement with an elapsed time greater than 
9 months to evaluate body composition. Exclusion crite-
ria included severe liver disease, renal impairment (esti-
mated glomerular filtration rate (GFR) [eGFR] < 15 mL/
min/1.73  m2 or undergoing renal replacement therapy), 
pregnancy, infectious diseases, and cancer. Finally, 312 
patients were enrolled in this retrospective study (Fig. 1). 
The median with interquartile range of the period 
between the first and second DXA measurement was 
1.04  years (0.94–1.42  years). The patients were divided 
Fig. 1  Flow chart
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into an insulin-treated group (N = 86) and non-insulin-
treated group (N = 216). The present study complied 
with the Declaration of Helsinki and was approved by the 
research ethics committee of Tokyo Medical and Dental 
University.
Measurement of Body Composition
To evaluate the SMI, fat and fat-free tissue mass were 
measured using whole-body DXA (Lunar iDXA, GE 
Healthcare, Madison, WI). The patients were positioned for 
whole-body scans in accordance with the manufacturer’s 
protocol. The whole-body fat-free mass was divided into 
several regions (e.g., arms, legs, and trunk). Appendicular 
muscle mass was estimated as the sum of the fat-free mass 
of both the upper and lower limbs. The SMI was calculated 
as the appendicular muscle mass divided by the square of 
the height (kg/m2). Grip strength (kg) was measured using 
the hand dynamometer Grip-D (TKK5401, Takei, Niigata, 
Japan). The average grip strength was used for muscle 
strength. According to the Asian sarcopenia criteria [3], an 
SMI <7.0 in males and <5.4 in females, as well as a grip 
strength <26.0 kg in males and <18.0 kg in females were 
defined as low muscle mass and reduced grip strength, 
respectively. Eventually, the patients with both low mus-
cle mass and reduced grip strength were diagnosed with 
sarcopenia. The annual changes in SMI, and the muscle 
mass in the upper and lower extremities (%/year) were also 
determined.
Clinical and Biochemical Analysis
Information was obtained from the patients’ medical 
records regarding the medications for diabetes, dyslipi-
demia, hypertension, hyperuricemia, and anti-platelet 
agents, duration of diabetes, diabetic retinopathy, history 
of cardiovascular disease (CVD), and smoking status. CVD 
was defined as the presence of a previous stroke, myocar-
dial infarction, or coronary revascularization procedure. 
Smoking history was classified as either current or non-
smokers. The systolic and diastolic blood pressures (SBP 
and DBP) were measured in a sitting position after at least 
5  min rest, using an electronic sphygmomanometer (ES-
H55, Terumo Inc., Tokyo, Japan). The BMI was calculated 
as the weight divided by the square of the height (kg/m2). 
Routine tests included alanine transaminase (ALT), aspar-
tate transaminase (AST), gamma-glutamyl transpeptidase 
(γ-GTP), high-density lipoprotein (HDL) and low-density 
lipoprotein (LDL) cholesterol, triglycerides, and uric acid. 
All tests were determined using standard laboratory pro-
cedures. The triglycerides-to-HDL cholesterol (TG/HDL-
C) ratio was used for the assessment of insulin resistance. 
HbA1c was measured using the latex agglutination method. 
Urinary albumin and creatinine excretion were measured in 
a spot urine collection by a turbidimetric immunoassay and 
enzymatic method. The ratio (ACR, mg/g) was used for the 
assessment of albuminuria. The GFR, ml/min/1.73 m2 was 
calculated using the equation for Japanese [17].
Statistical Analysis
Statistical analysis was carried out using IBM SPSS ver-
sion 21.0 (IBM, Armonk, NY, USA), and the results 
were expressed as the mean ± SD, median, and inter-
quartile range or percentages. A T-test, Mann–Whitney 
U test, or Chi-square test as appropriate were used for 
group comparisons (with insulin vs. without insulin). 
Linear regression analyses with a stepwise procedure 
were used to assess the factors associated with a 1-year 
change in SMI. The examined putative risk factors con-
sisted of the duration of diabetes, smoking status, his-
tory of CVD, grip strength, BMI, SBP, TG/HDL-C 
ratio, HbA1c, eGFR, as well as the use of insulin, oral 
hypoglycemic agents, angiotensin receptor blockers, 
and statins (multivariate model 1). Age and gender were 
forced into the models because these are strong determi-
nants of muscle mass and function. We also determined 
the 1-year changes in HbA1c, BMI, and other markers 
Fig. 2  Annual changes in skel-
etal muscle index (mean ± SE, 
%) in appendicular (left), upper 
extremities (middle), and lower 
extremities (right) in patients 
with type 2 diabetes in the pro-
pensity score-matched cohort. 
White and black bars indicate 
non-insulin-treated and insulin-
treated group
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for cardiometabolic risks, including lipid and uric acid 
levels. We also examined the correlation for the change 
in SMI with the changes in these parameters (Pearson 
correlation). We then created a multivariate regression 
model (multivariate model 2) in which the covariates 
that were significantly correlated with a change in SMI 
and the covariates selected in the multivariate model 1 
were entered. Finally, we performed propensity score 
(PS) matching to eliminate any possible treatment bias. 
The PS was calculated using multivariable logistic 
regression models that included the following parame-
ters: age, gender, BMI, HbA1c, and duration of diabetes, 
logarithmically transformed urinary ACR, and eGFR. 
For the calculation of the PS, the dependent variable was 
insulin treatment at baseline. We performed 1:1 match-
ing on the PS using nearest neighbor matching with a 
maximum caliber of 0.01 of the PS. The annual change 
in SMI (mean ± SE) was compared between the insulin-
treated and non-insulin-treated patients using analysis of 
covariance (ANCOVA). The differences were considered 
to be statistically significant at a p-value less than 0.05.
Results
A total of 312 Japanese patients with type 2 diabetes (mean 
age: 64 ± 11 years; 40.8% female; range: 21–89 years old) 
were studied. Table 1 presents the clinical characteristics of 
the study participants. The insulin-treated patients exhib-
ited significantly higher levels of SBP and urinary ACR, a 
longer duration of diabetes, higher prevalence of diabetic 
retinopathy, and lower levels of grip strength, triglycerides, 
AST, ALT, and eGFR than the non-insulin-treated patients. 
As shown in Table  2, the insulin-treated patients were 
significantly more likely to receive diuretics and calcium 
channel blockers, but less likely to receive sulfonylureas 
and dipeptidyl peptidase-4 (DPP4) inhibitors than the non-
insulin-treated patients.
As shown in Table 3, insulin treatment was found to be 
protective against the annual decline of SMI in the univari-
ate and gender- and age-adjusted models. In the multivari-
ate model, which includes the duration of diabetes and BMI 
in addition to age and gender as covariates (multivariate 
model 1), the patients with treated with insulin were at a 
significantly lower risk for the decline of SMI than those 
who did not receive insulin treatment. In addition, insulin 
Table 1  Clinical characteristics 
in patients with type 2 diabetes
ALT alanine transaminase, AST aspartate transaminase, eGFR estimated glomerular filtration ratio, GTP 
glutamyl transpeptidase, HDL high-density lipoprotein, LDL low-density lipoprotein, TG triglycerides
Insulin (−) (N = 216) Insulin (+) (N = 86) p-values
Age (years) 63 ± 12 66 ± 12 0.031
Gender (% female) 38 42 0.610
Systolic blood pressure (mmHg) 126 ± 15 130 ± 16 0.031
Diastolic blood pressure (mmHg) 75 ± 13 75 ± 15 0.774
Body mass index (kg/m2) 25.1 ± 4.6 24.3 ± 3.8 0.172
Grip strength (kg) 29.4 (20.3–36.5) 22.9 (17.2–30.3) 0.001
Skeletal muscle index 6.7 (5.9–7.6) 6.4 (5.8–7.2) 0.263
Body fat (%) 33.6 ± 7.1 34.3 ± 8.5 0.549
Duration of diabetes (years) 6 (3–9) 10 (3–18) <0.001
Proliferative diabetic retinopathy (%) 2 17 <0.001
Previous cardiovascular disease (%) 11 9 0.729
Current smoking (%) 11 13 0.501
HbA1c (mmol/mol) 51.7 ± 15.4 61.9 ± 15.4 <0.001
HbA1c (%) 6.9 ± 1.4 7.8 ± 1.4
TG (mmol/l) 1.37 (1.02–2.35) 1.15 (0.89–2.02) 0.034
HDL cholesterol (mmol/l) 1.49 ± 0.42 1.58 ± 0.45 0.133
TG/HDL cholesterol ratio 2.15 (1.39–3.95) 1.91 (1.13–3.78) 0.271
LDL cholesterol (mmol/l) 2.82 (2.41–3.34) 2.84 (2.22–3.49) 0.416
AST (U/l) 23 (21–32) 21 (19–25) 0.004
ALT(U/l) 23 (17–35) 18 (15–27) 0.001
γ-GTP (U/l) 35 (22–62) 31 (20–46) 0.051
Uric acid (μmol/l) 312 (274–364) 312 (262–372) 0.648
Albumin-to-creatinine ratio (mg/g) 22 (14–59) 32 (14–133) 0.042
eGFR (ml/min/1.73 m2) 75.5 ± 19.7 69.6 ± 27.6 0.035
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treatment was significantly and positively associated with 
the annual change in the muscle mass of the lower extremi-
ties (standardized β 0.213; p = 0.015) but not with that of 
the upper extremities (standardized β −0.012; p = 0.892) 
in the multivariate models. Since the 1-year change in 
SMI was significantly correlated with the BMI (r = 0.279; 
p < 0.001) and HbA1c (r = −0.162; p = 0.043) levels, we 
constructed a multivariate model in which the changes in 
BMI and HbA1c were added as covariates (multivariate 
model 2). In the model, insulin treatment was shown to be 
protective against a decline in SMI with a statistical signifi-
cance. Insulin treatment was significantly associated with 
SMI in the lower but not the upper extremities in the mul-
tivariate models. Other significant covariates included in 
the model were the duration of diabetes and BMI at base-
line. Although grip strength was strongly correlated with 
SMI (r = 0.637; p < 0.001) and SMI in the upper (r = 0.733; 
p < 0.001) and lower (r = 0.570; p < 0.001) extremities at 
baseline, grip strength was not correlated with the change 
in SMI (r = −0.032; p = 0.674) and SMI in the upper 
(r = 0.031; p = 0.680) and lower (r = −0.050, p = 0.509) 
extremities. Finally, grip strength was not selected in the 
multivariate models.
In a propensity-matched cohort (Fig.  2), insulin treat-
ment significantly increased the SMI in 1-year (mean ± SE) 
compared with the non-insulin-treated group (2.40 ± 0.98% 
Table 2  Medications for patients with type 2 diabetes
ACEIs angiotensin converting enzyme inhibitors, ARBs angioten-
sin receptor blockers, DPP4 dipeptidyl peptidase 4, GIs glycosi-
dase inhibitors, GLP1-R glucagon-like peptide 1 receptors, SGLT2 






Sulfonylureas (%) 18 4 0.002
Biguanides (%) 25 22 0.662
Alpha-GIs (%) 5 8 0.241
Glinides (%) 3 2 0.817
TZDs (%) 5 4 0.861
DPP4 inhibitors (%) 36 22 0.021
GLP1-R agonists (%) 2 1 0.666
SGLT2 inhibitors (%) 2 0 0.369
ACEIs (%) 4 3 0.775
ARBs (%) 33 41 0.153
Calcium channel blockers (%) 27 46 0.001
Beta-blockers (%) 12 9 0.553
Alpha-blockers (%) 2 2 0.799
Diuretics (%) 7 16 0.014
Statins (%) 29 39 0.076
Fibrates (%) 2 4 0.289
Ezetimibe (%) 5 2 0.280
Uric acid-lowering agents (%) 7 5 0.539
Anti-platelet agents (%) 11 18 0.116
Table 3  Factors associated 
with 1-year change in skeletal 
muscle mass in patients with 
type 2 diabetes
A-R2 adjusted  R2, BMI body mass index, NS not selected in the model, SMI skeletal muscle index
SMI SMI in the upper 
extremities
SMI in the lower 
extremities
Standardized β p-values Standardized β p-values Standardized β p-values
Univariate (A-R2 = 0.114) (A-R2 = 0.001) (A-R2 = 0.119)
 Insulin 0.177 0.041 −0.023 0.760 0.169 0.045
Age- and gender-adjusted (A-R2 = 0.117) (A-R2 = 0.008) (A-R2 = 0.123)
 Insulin 0.175 0.042 −0.012 0.873 0.174 0.038
 Age −0.064 0.471 0.074 0.328 −0.049 0.514
 Gender −0.021 0.983 0.054 0.468 −0.042 0.575
Multivariate 1 (A-R2 = 0.165) (A-R2 = 0.008) (A-R2 = 0.197)
 Insulin 0.195 0.025 −0.012 0.892 0.213 0.015
 Age −0.139 0.132 0.074 0.328 −0.071 0.387
 Gender 0.024 0.771 0.054 0.468 −0.030 0.682
 Duration of diabetes −0.301 0.001 NS −0.182 0.021
 Body mass index −0.188 0.036 NS −0.220 0.005
Multivariate 2 (A-R2 = 0.177) (A-R2 = 0.018) (A-R2 = 0.215)
 Insulin 0.184 0.042 −0.023 0.768 0.173 0.035
 Age −0.062 0.554 −0.035 0.664 −0.024 0.782
 Gender 0.007 0.933 0.061 0.427 −0.018 0.810
 Duration of diabetes −0.298 0.001 NS −0.166 0.038
 BMI −0.208 0.042 NS −0.180 0.027
 Change in BMI 0.080 0.418 0.094 0.228 0.138 0.075
 Change in HbA1c −0.097 0.272 −0.054 0.497 −0.044 0.562
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vs. −0.43 ± 0.98%; p = 0.050). When the effect of insulin 
was determined separately for the muscle mass of the upper 
and lower extremities, insulin significantly attenuated the 
decline of muscle mass in the lower extremities but not in 
the upper extremities (Fig. 2).
Finally, we investigated whether the change in SMI in 
patients treated with insulin could be correlated with body 
fat (android and gynoid) and cardiometabolic risk fac-
tors. The change in SMI was not correlated with that in 
the android (r = 0.092; p = 0.247) and gynoid (r = 0.031; 
p = 0.409). In addition, the change in SMI was significantly 
correlated with that in HbA1c (r = −0.150; p = 0.047), HDL 
cholesterol (r = 0.244; p = 0.034), and uric acid (r = −0.310; 
p = 0.009) but not with triglycerides (r = −0.068; p = 0.308), 
LDL cholesterol (r = −0.049; p = 0.360), AST (r = −0.010; 
p = 0.471), ALT (r = −0.013; p = 0.460), or gamma GTP 
(r = 0.092; p = 0.247).
Discussion
Diabetes is a strong risk factor for the progression of sarco-
penia and insulin activity is critical to maintain the balance 
of muscle protein synthesis and degradation [5]. There is 
a close association between insulin resistance and sarcope-
nia. Skeletal muscle is highly responsible for insulin-stim-
ulated glucose uptake which accounts for approximately 
75% of the glucose uptake of the entire body. It has been 
suggested that people with high muscle mass could have 
increased capacity of glucose uptake and insulin sensitiv-
ity in the skeletal muscle and vice versa. In observational 
and interventional studies [14, 18], insulin sensitizers can 
increase muscle mass with an improvement in mitochon-
drial activity and decreased protein degradation in skel-
etal muscle mass. However, it is uncertain whether insu-
lin treatment could attenuate the loss of skeletal muscle 
mass and/or function [19, 20]. In addition, the long-term 
effects of insulin treatment on muscle mass and strength are 
unknown. In this study, we revealed that insulin treatment 
significantly attenuated the decline of skeletal muscle mass 
in patients with type 2 diabetes. This association remained 
when we used PS matching.
The protective effect of insulin on the reduction of mus-
cle mass was primarily observed in the lower extremities 
(Table  3; Fig.  2). Although the protective mechanism of 
insulin on the progression of muscle dysfunction that was 
dominant in the lower extremities remains unclear, some 
previous reports provide important speculation [21, 22]. 
Patients with diabetes, especially those with a longer dura-
tion of the disease are at an increased risk for poor mus-
cle strength in the quadriceps [21] and walking impair-
ments [22]. These data suggest the possibility that patients 
with a long duration of diabetes are more likely to develop 
muscle dysfunction in the lower extremities rather than in 
the upper extremities. Compared with the diabetic patients 
who have had the disease for a short duration, those with a 
long duration exhibit low endogenous insulin levels in the 
bloodstream, implying that insulin signaling in the skeletal 
muscle may be impaired. This results in low muscle mass 
and decreased function in diabetic patients with a long 
duration of diabetes. Thus, it is possible that an efficient 
supply of exogenous insulin could improve insulin signal-
ing in the skeletal muscle, promote protein synthesis, and 
protect against the loss of muscle mass among patients with 
diabetes, especially those with a long duration of diabetes. 
In addition, we used a multivariate model to identify the 
1-year changes in the HbA1c and BMI levels as covariates 
that insulin treatment remained to significantly increase 
muscle mass. These findings provide evidence that the pro-
tective effects of insulin treatment on the decline of mus-
cle mass may be independent of an improvement in glyce-
mic control or load increase. Therefore, the resolution of 
the relative insufficiency of insulin via exogenous insulin 
injections may be the main factor with regards to the pro-
tection of muscle mass in this study. We further determined 
whether the change in SMI in patients with insulin treat-
ment was correlated with that in body fat and cardiomet-
abolic risk factors. We found that the change in SMI was 
indeed correlated with the change in HbA1c, HDL choles-
terol, and uric acid. These data suggest that the increase in 
muscle mass induced by insulin treatment may reflect an 
improvement in peripheral insulin resistance. Based on 
our findings and the results from previous studies [21, 22], 
insulin treatment could be plausible means of preserving 
muscle function while also improving the glycemic control 
of patients with diabetes who are affected by low muscle 
mass and strength in the lower extremities.
Combined with the potential of insulin treatment to 
preserve muscle function and mass, it should be empha-
sized that insulin treatment should be initiated with 
the careful consideration of adverse effects, particu-
larly hypoglycemia. Hypoglycemia increases the risk of 
dementia, falls, cardiovascular events and mortality in 
elderly patients with diabetes [23]. In particular, falls are 
the major cause of injury and a significant source of mor-
bidity and disability which can severely reduce the QOL 
among the elderly. Comorbidities (e.g., chronic kidney 
disease) further increase the risk for hypoglycemia in 
elderly patients with diabetes. In addition, insulin treat-
ment has the potential to increase body fat. The accumu-
lation of body fat, particularly abdominal visceral fat, has 
been recognized as a strong contributor to the develop-
ment of CVD and metabolic disorders, including diabe-
tes [24, 25]. Therefore, physicians should balance the 
potential benefits and risks when recommending the use 
of insulin.
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In addition to insulin treatment, the durations of diabe-
tes and BMI were found to be significant predictors for the 
changes in SMI in this study (Table 3). Moreover, the pres-
ence of diabetes, poor glycemic control, and insulin resist-
ance have been reported to increase the risk for lowering 
muscle mass and function in elderly individuals [5, 7, 8, 13, 
26]. Therefore, it is conceivable that patients with a long 
duration of diabetes may be exposed to hyperglycemia and 
insulin resistance much longer than those with a short dura-
tion of diabetes, resulting in a reduction of muscle mass 
and function. In contrast, the negative association of the 
BMI with a change in SMI seems odd since patients with a 
high BMI are subjected to a high load (high body weight) 
and may be protective against the loss of muscle mass and 
function. One potential explanation is that patients with a 
high BMI are more likely to be obese and those who lost 
more weight (fat and non-fat mass) than non-obese patients 
via calorie restriction during the follow-up period, would 
exhibit a reduction in the SMI; however, no information 
regarding diet was available in this study.
This study has several limitations: (1) generalization of 
the findings of this study is limited due to the study design 
(hospital-based study including only Japanese individuals 
with type 2 diabetes); (2) propensity scores do not elimi-
nate bias if there are unmeasured confounders; (3) informa-
tion regarding changes in grip strength was not available 
and the follow-up period for muscle mass was relatively 
short; (4) we were unable to obtain data regarding diet and 
exercise, or diabetic neuropathy, all of which may affect 
muscle function; (5) we measured the grip strength in both 
the dominant and non-dominant hands once and used the 
average values to assess the degree of muscle strength 
in this study. Recently, a standardized protocol for grip 
strength measurements was suggested by Roberts HC et al. 
to improve the assessment of sarcopenia [27]. The pro-
tocol proposes that three measurements of grip strength 
should be conducted for each hand, and the maximal grip 
score obtained from all six trials should be used as the grip 
strength in the statistical analysis. Therefore, we should 
have measured a grip strength in accordance with this pro-
tocol; and (6) there was a significant difference in the age 
between the patients treated with insulin and those who 
were not. Sarcopenia occurs with advancing age (aging is 
the strongest contributor to the progression of sarcopenia); 
therefore, age differences could influence the outcome data, 
particularly regarding the effect of insulin treatment on 
muscle mass; however, insulin treatment was significantly 
associated with preserved muscle mass even after adjust-
ing for covariates, including aging. Furthermore, it should 
be considered that the older age of patients receiving insu-
lin treatment may underestimate but not overestimate the 
favorable effects of insulin treatment on muscle mass.
In summary, our data suggest that patients with type 
2 diabetes treated with insulin may be at a lower risk for 
the loss of skeletal muscle mass in the lower extremities, 
compared with those who do not receive insulin treatment. 
Whether the administration of insulin influences the inci-
dent sarcopenia in randomized controlled trials remains to 
be elucidated.
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